Metavia Inc (MTVA)

$1.03 +0.05 (4.86%)
Market Cap 24.92M
Revenue (ttm) 0.00
Net Income (ttm) -27.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 125,400
Avg Vol 2,105,802
Day's Range N/A - N/A
Shares Out 24.20M
Stochastic %K 68%
Beta 0.37
Analysts Strong Sell
Price Target $13.75

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 702 9600
Address:
545 Concord Avenue, Suite 210, Cambridge, United States
Chinna11
Chinna11 Oct. 1 at 10:02 PM
$MTVA It's about to gain some momentum and keep an eye on it !
0 · Reply
Basko151
Basko151 Oct. 1 at 3:42 PM
$MTVA LFG!!
0 · Reply
Kertzi
Kertzi Oct. 1 at 4:27 AM
$MTVA Insider trading continues and no one cares, as we see e.g. in the Mullen/Bollinger case. The US Nasdaq and the SEC are enabling and allowing scams and criminal activities.
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 30 at 9:02 AM
🚀 New Signal ✅ 💊 $MTVA 🗓️ Sep 30, 2025 💵 Entry: $0.9650 🎯 Target (Opt.): $1.15 (+18.93%) 👉 Check bio for full access
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 25 at 3:04 AM
$RADX https://x.com/teamradiopharm/status/1970689873301668003?s=46 $MTVA
0 · Reply
BULLISH1975
BULLISH1975 Sep. 24 at 4:13 PM
$ICU $MTVA $CLNN $KZIA looking for a micro cap with phase III interim due plus much more in coming days!!! see dd below! i think you will be glad you took a close look!!!! good luck
2 · Reply
Basko151
Basko151 Sep. 24 at 3:06 PM
$MTVA Am I the only one Buying???
0 · Reply
Chinna11
Chinna11 Sep. 22 at 10:20 AM
$MTVA push something here
0 · Reply
peepthestamp
peepthestamp Sep. 21 at 3:50 PM
$SKYQ $PT $VEEA $ALXO $MTVA
0 · Reply
The_Beyonder
The_Beyonder Sep. 20 at 7:23 PM
Seems like most bulls are watching ticker BOXL next week. BOXL has been beaten down by shorts, its super undervalued at the current price. It's most likely time BOXL sees a squeeze, you don't want to miss out on this! Watching... $DFSC $IZEA $WLDS $MTVA
0 · Reply
Latest News on MTVA
MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 26, 2025, 8:31 AM EDT - 5 weeks ago

MetaVia to Present at Upcoming Investor and Industry Conferences

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:31 AM EDT - 2 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 6, 2025, 8:31 AM EDT - 2 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Aug 4, 2025, 8:31 AM EDT - 2 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jul 9, 2025, 8:31 AM EDT - 3 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 21, 2025, 9:00 AM EDT - 3 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 10, 2025, 8:31 AM EDT - 4 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

Jun 4, 2025, 8:31 AM EDT - 4 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 5 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 9, 2025, 8:01 AM EDT - 5 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

May 7, 2025, 2:00 AM EDT - 5 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 5 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 22, 2025, 8:31 AM EDT - 5 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Apr 15, 2025, 7:01 AM EDT - 6 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 7:31 AM EDT - 7 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Jan 10, 2025, 8:05 AM EST - 9 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 18, 2024, 8:01 AM EST - 11 months ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 13, 2024, 8:01 AM EST - 11 months ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 8:01 AM EST - 11 months ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Nov 4, 2024, 8:01 AM EST - 11 months ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 25, 2024, 5:08 PM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 24, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

Jun 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

May 22, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 17, 2024, 8:05 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Apr 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Mar 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 29, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Feb 12, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Feb 1, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Jan 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 9, 2024, 8:30 AM EST - 1 year ago

NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

NeuroBo to Participate in Industry and Investor Conferences in January

Jan 2, 2024, 8:01 AM EST - 1 year ago

NeuroBo to Participate in Industry and Investor Conferences in January

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Dec 28, 2023, 8:45 AM EST - 1 year ago

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 19, 2023, 8:43 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

NeuroBo to Participate in Investor Conferences in December

Dec 1, 2023, 8:31 AM EST - 2 years ago

NeuroBo to Participate in Investor Conferences in December

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 4:05 PM EST - 2 years ago

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Chinna11
Chinna11 Oct. 1 at 10:02 PM
$MTVA It's about to gain some momentum and keep an eye on it !
0 · Reply
Basko151
Basko151 Oct. 1 at 3:42 PM
$MTVA LFG!!
0 · Reply
Kertzi
Kertzi Oct. 1 at 4:27 AM
$MTVA Insider trading continues and no one cares, as we see e.g. in the Mullen/Bollinger case. The US Nasdaq and the SEC are enabling and allowing scams and criminal activities.
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 30 at 9:02 AM
🚀 New Signal ✅ 💊 $MTVA 🗓️ Sep 30, 2025 💵 Entry: $0.9650 🎯 Target (Opt.): $1.15 (+18.93%) 👉 Check bio for full access
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 25 at 3:04 AM
$RADX https://x.com/teamradiopharm/status/1970689873301668003?s=46 $MTVA
0 · Reply
BULLISH1975
BULLISH1975 Sep. 24 at 4:13 PM
$ICU $MTVA $CLNN $KZIA looking for a micro cap with phase III interim due plus much more in coming days!!! see dd below! i think you will be glad you took a close look!!!! good luck
2 · Reply
Basko151
Basko151 Sep. 24 at 3:06 PM
$MTVA Am I the only one Buying???
0 · Reply
Chinna11
Chinna11 Sep. 22 at 10:20 AM
$MTVA push something here
0 · Reply
peepthestamp
peepthestamp Sep. 21 at 3:50 PM
$SKYQ $PT $VEEA $ALXO $MTVA
0 · Reply
The_Beyonder
The_Beyonder Sep. 20 at 7:23 PM
Seems like most bulls are watching ticker BOXL next week. BOXL has been beaten down by shorts, its super undervalued at the current price. It's most likely time BOXL sees a squeeze, you don't want to miss out on this! Watching... $DFSC $IZEA $WLDS $MTVA
0 · Reply
Basko151
Basko151 Sep. 19 at 5:29 PM
$MTVA I see a bull flag on the 1hr, hopefully we get confirmation into the weekend!!
2 · Reply
smoketuna
smoketuna Sep. 19 at 7:52 AM
$MTVA 85% with 🎯 TunaSignal.ai score! while price $1.04 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
TraderJay85
TraderJay85 Sep. 18 at 9:37 PM
All these are setting up and should be on close watch. $MTVA $ANGX $NAOV $GORV $QNRX
1 · Reply
Kertzi
Kertzi Sep. 18 at 5:17 PM
$MTVA When $23? @ZacksSCR
1 · Reply
TraderRapp
TraderRapp Sep. 18 at 3:51 PM
$MTVA where did all that 73Million share volume go the other day? literally all one day then nothing.
1 · Reply
Chinna11
Chinna11 Sep. 18 at 3:12 PM
$MTVA Damm
0 · Reply
Chinna11
Chinna11 Sep. 18 at 3:13 AM
$MTVA More likely a Bad News but cash burn rate is a good part here ! https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mtva/metavia/news/were-keeping-an-eye-on-metavias-nasdaqmtva-cash-burn-rate?utm_medium=article&utm_source=robinhood
0 · Reply
Arttab
Arttab Sep. 17 at 8:48 PM
$MTVA manipulation as it’s finest.. Remember NRBO folks
1 · Reply
Chinna11
Chinna11 Sep. 17 at 8:22 PM
$MTVA fuk this
0 · Reply
DJIA40K
DJIA40K Sep. 17 at 8:16 PM
$MTVA ha ha ha ha. losers. see you .25 shortly......
0 · Reply
DJIA40K
DJIA40K Sep. 17 at 8:10 PM
$MTVA OFFERING INCOMING
2 · Reply
GMExAPE
GMExAPE Sep. 17 at 7:44 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. watching $GORV $UBXG $CJET $MTVA $TOPP
0 · Reply